Iterum Therapeutics plc ITRM 深 滬
已收盤 07-18 16:00:00 美东时间
0.9166
-0.063
-6.47%
華盛通- 最 高0.9775
- 今 開0.9088
- 成交量 183.12万股
- 最 低 0.88
- 昨 收 0.98
- 總市值 3666.40万
- 52周最高 3.02
- 市盈率 靜 --
- 換手率 4.58%
- 52周最低 0.808
- 委 比 77.78%
- 總股本 4000.00万
- 歷史最高 195.00
- 量 比 1.97
- 振 幅 9.95%
- 歷史最低 0.622
- 每 手 1
- 風險率 0.35%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Iterum Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Iterum Therapeutics授予新任首席商业化官Christine Coyne 20万股股票期权，行权价为每股0.97美元，期权有效期10年，分四年归属，每年25%。期权授予基于Nasdaq新员工激励规定，经薪酬委员会批准。Iterum专注于开发抗生素治疗耐药感染，其主要产品sulopenem已获FDA批准用于治疗尿路感染。
07-02 20:30
Iterum Names Christine Coyne as Chief Commercial Officer to Lead ORLYNVAH™ Launch and Commercial Growth
Iterum Therapeutics appointed Christine Coyne as Chief Commercial Officer to lead the U.S. launch of ORLYNVAH™ and future commercialization efforts. With over 30 years of experience, Coyne brings significant expertise in anti-infectives, aiming to accelerate ORLYNVAH™'s success and long-term growth for the company. ORLYNVAH™ is an oral penem antibiotic targeting uUTIs caused by multi-drug resistant pathogens.
06-30 11:00
Iterum Shares Phase 3 Trial Results Showing How Its Oral Antibiotic Compares to Augmentin for UTIs
Iterum Therapeutics plc (NASDAQ:ITRM) (the "Company" or "Iterum"), a company focused on delivering next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both community
06-25 19:06
Iterum Therapeutics Announces Publication of REASSURE Trial in NEJM Evidence
Iterum Therapeutics reported that 9.2% of patients in the REASSURE trial had baseline pathogens resistant to three or more antibiotic classes. Results from the Phase 3 trial, published in *NEJM Evidence*, showed oral sulopenem was non-inferior and statistically superior to Augmentin® for treating uncomplicated urinary tract infections (uUTI), with a 61.7% success rate vs. 55.0%. The U.S. FDA approved ORLYNVAH™, an oral sulopenem, for uUTIs caused...
06-25 11:00
Iterum Therapeutics Announces Partnership for Commercialization Services
Iterum Therapeutics has partnered with EVERSANA to commercialize ORLYNVAH™, an oral penem antibiotic, in the U.S. by Q4 2025. The agreement includes sales, marketing, and logistics support. ORLYNVAH™ targets hard-to-treat uncomplicated urinary tract infections and marks the first oral penem available in the U.S. The companies aim to address antibiotic resistance and improve patient access to effective treatments. A conference call discussing this...
06-11 11:00
Iterum Gets Pfizer to Extend $20M Milestone Payment for ORLYNVAH Approval to 2029
Iterum Therapeutics plc (NASDAQ:ITRM) (the "Company" or "Iterum"), a company focused on delivering next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both community
05-19 19:12
Iterum Therapeutics Non-GAAP EPS of -$0.10
Iterum Therapeutics press release (NASDAQ:ITRM): Q1 Non-GAAP EPS of -$0.10. Cash and cash equivalents were $12.7 million as of March 31, 2025. Based on Iterum’s current operating plan, Iterum expects ...
05-13 19:05
Earnings Scheduled For May 13, 2025
Companies Reporting Before The Bell • Endeavour Silver (NYSE:EXK) is estimated ...
05-13 16:32
HC Wainwright & Co. Assumes Iterum Therapeutics at Buy, Announces Price Target of $9
HC Wainwright & Co. analyst Joseph Pantginis assumes Iterum Therapeutics (NASDAQ:ITRM) with a Buy rating and announces Price Target of $9.
05-08 19:04
Earnings Scheduled For February 7, 2025
Companies Reporting Before The Bell • Cboe Global Markets (BATS:CBOE) is expect...
02-07 16:32
